利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.037 秒)

    Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes
    32.
    发明授权
    Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes 失效
    编码CTL或T辅助细胞表位的重组VP2 paraviral伪粒子

    公开(公告)号：US06458362B1

    公开(公告)日：2002-10-01

    申请号：US08704867

    申请日：1996-08-30

    申请人： Ignacio Casal ,  Christine Sedlik ,  Javier Sarraseca ,  Richard Lo-Man ,  Paloma Rueda ,  Claude Leclerc

    发明人： Ignacio Casal ,  Christine Sedlik ,  Javier Sarraseca ,  Richard Lo-Man ,  Paloma Rueda ,  Claude Leclerc

    IPC分类号： A61K3912

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N2730/10122 ,  C12N2750/14322 ,  Y10S977/804

    摘要： Attempts to generate modified viral pseudo-particles that are capable of stably incorporating heterologous antigenic determinants has encountered a number of difficulties including inhibition of pseudo-particle formation following epitope insertion and failure of the epitope to retain its native configuration. The present invention is directed toward recombinant viral pseudo-particles of the family Parvoviridae that stably encode heterologous epitopes. Hybrid virus-like particles (VLP) were prepared by self-assembly of a modified porcine parvovirus (PPV) VP2 capsid protein carrying a CD8+ or CD4+ T cell epitope in the amino terminus. Immunization of mice with hybrid pseudo-particles carrying a lymphocytic choriomeningitis virus (LCMV) nucleoprotein CTL epitope, without adjuvant, induced strong cytotoxic T lymphocyte (CTL) responses against both peptide-coated- or virus-infected-target cells. Immunization of mice with hybrid pseudo-particles carrying a hepatitis B virus (HBV) T helper cell epitope, without adjuvant, induced strong T helper lymphocyte responses against the reporter epitope. These recombinant viral pseudo-particles are easily produced by the baculovirus expression system and, therefore, represent a promising and safe strategy to induce strong CTL and T-helper cell responses for the elimination of virus-infected cells.

    摘要翻译： 产生能够稳定地掺入异源抗原决定簇的修饰的病毒伪粒子的尝试遇到了许多困难，包括在表位插入之后抑制伪粒子形成，以及表位失效以保持其天然构型。 本发明涉及稳定编码异源表位的细小病毒科的重组病毒假颗粒。 通过在氨基末端携带具有CD8 +或CD4 + T细胞表位的修饰的猪细小病毒（PPV）VP2衣壳蛋白自组装来制备杂交病毒样颗粒（VLP）。 用携带淋巴细胞性脉络丛脑膜炎病毒（LCMV）核蛋白CTL表位的混合假颗粒免疫小鼠，无佐剂，诱导针对肽包被或病毒感染的靶细胞的强的细胞毒性T淋巴细胞（CTL）反应。 携带乙型肝炎病毒（HBV）T辅助细胞表位的混合假颗粒免疫小鼠，无佐剂，诱导针对报告基因表位的强T辅助淋巴细胞反应。 这些重组病毒假颗粒易于通过杆状病毒表达系统产生，因此代表了诱导强大的CTL和T辅助细胞应答以消除病毒感染细胞的有希望且安全的策略。

    THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE
    34.
    发明申请
    THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE 审中-公开
    根据免疫应答的自适应，消除和/或法规组成部分治疗癌症

    公开(公告)号：US20100150999A1

    公开(公告)日：2010-06-17

    申请号：US12439379

    申请日：2007-07-16

    申请人： Claude Leclerc ,  Pedro Berraondo Lopez

    发明人： Claude Leclerc ,  Pedro Berraondo Lopez

    IPC分类号： A61K9/127 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/555 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/33 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/88 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12Y406/01001

    摘要： The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient.

    摘要翻译： 本发明涉及一种适合用于癌症治疗的试剂盒，其中所述试剂盒包括：（i）包含一个或几个携带一个或几个肿瘤相关抗原表位的多肽的重组蛋白，所述多肽 插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中所述CyaA片段保留所述腺苷酸环化酶蛋白质的特性以靶向抗原呈递细胞或其重要蛋白质的混合物，其中至少 所述表位之一或肿瘤相关抗原或CyaA蛋白的插入位点或所述CyaA蛋白的片段在混合物中的各种重组蛋白之间是不同的; 并且所述试剂盒的部分还包含至少一种以下化合物; （ii）任选的适于调节患者的调节免疫应答的药剂; （iii）适合于激活患者中先天免疫应答的辅助成分。

    Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
    36.
    发明授权
    Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof 有权
    包含其的多抗原糖肽糖蛋白疫苗及其应用

    公开(公告)号：US06676946B2

    公开(公告)日：2004-01-13

    申请号：US09405986

    申请日：1999-09-27

    申请人： Sylvie Bay ,  Daniele Cantacuzene ,  Claude Leclerc ,  Richard Lo-Man ,  Sophie Vicher-Guerre

    发明人： Sylvie Bay ,  Daniele Cantacuzene ,  Claude Leclerc ,  Richard Lo-Man ,  Sophie Vicher-Guerre

    IPC分类号： A61K39385

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K47/645 ,  A61K2039/55505 ,  A61K2039/645 ,  C07K9/001 ,  C07K14/001 ,  C07K14/22 ,  C07K14/285 ,  C07K14/31 ,  C07K14/315 ,  Y02A50/466

    摘要： A carbohydrate peptide conjugate containing: (i) a carrier containing a dendrimeric poly-lysine enabling multiple epitopes to be covalently attached thereto, (ii) at least one peptide containing one T epitope or several identical or different T-epitopes, (iii) at least one carbohydrate moiety which is tumor antigen, or a derivative thereof, containing a B epitope, provided it is not a sialoside, or several identical or different epitopes, wherein said conjugate containing at least 3-lysines and up to 15 lysine covalently linked to one another, and wherein: (a) to the NH2 and of at least two lysine residues is bound at least one carbohydrate residue being not a sialoside, optionally substituted and containing an epitope and wherein the peptide containing one T epitope is covalently bound to the end of said carbohydrate which induces immune responses.

    摘要翻译： 一种碳水化合物肽缀合物，其含有：（i）含有多个表位与其共价连接的树状多聚赖氨酸的载体，（ii）至少一种含有一个T表位或几个相同或不同T表位的肽，（iii） 至少一个是含有B表位的肿瘤抗原或其衍生物的碳水化合物部分，只要它不是唾液酸苷或几个相同或不同的表位，其中所述含至少3个赖氨酸和至多15个赖氨酸的缀合物共价连接到 并且其中：（a）到NH 2和至少两个赖氨酸残基的至少一个碳水化合物残基不是唾液酸苷，任选地被取代并含有表位，并且其中含有一个T表位的肽共价结合到 所述碳水化合物的末端诱导免疫应答。

    Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
    40.
    发明授权
    Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response 有权
    基于针对免疫应答的适应性，先天和/或调节组分的癌症治疗

    公开(公告)号：US09095537B2

    公开(公告)日：2015-08-04

    申请号：US11778267

    申请日：2007-07-16

    申请人： Claude Leclerc ,  Pedro Berraondo Lopez

    发明人： Claude Leclerc ,  Pedro Berraondo Lopez

    IPC分类号： A61K39/10 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  C12N9/88

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/555 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/33 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/88 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12Y406/01001

    摘要： The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises:(i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient.

    摘要翻译： 本发明涉及一种适合用于癌症治疗的试剂盒，其中所述试剂盒包括：（i）包含一个或几个携带一个或几个肿瘤相关抗原表位的多肽的重组蛋白，所述多肽 插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中所述CyaA片段保留所述腺苷酸环化酶蛋白质的特性以靶向抗原呈递细胞或其重要蛋白质的混合物，其中至少 所述表位之一或肿瘤相关抗原或CyaA蛋白的插入位点或所述CyaA蛋白的片段在混合物中的各种重组蛋白之间是不同的; 并且所述试剂盒的部分还包含至少一种以下化合物; （ii）任选的适于调节患者的调节免疫应答的药剂; （iii）适合于激活患者中先天免疫应答的辅助成分。